Zimmer Biomet(NYSE) ZBH

Zimmer Biomet Holdings, Inc. makes artificial joints to help people move. Their products repair damage in knees, hips, and other bones. Surgeons use these tools to treat patients with bone injuries.

Tools for Bone and Muscle Repair

• Knees: Artificial joints and products used in knee replacement surgeries; generated $1.7 billion in net sales during the six-month period ended June 30, 2026.
• Hips: Replacement joints and repair solutions for hip procedures; accounted for $1.1 billion in net sales during the six-month period ended June 30, 2026.
• S.E.T.: Products for sports medicine, extremities, and trauma, including tools for face and chest surgery; totaled $1.1 billion in net sales during the six-month period ended June 30, 2026.
• Technology and Surgical: Robotic-assisted surgery platforms and bone cement used to fix joints to bone; earned $371.2 million in net sales during the six-month period ended June 30, 2026.

Strategic Growth and Integration

• Acquired Paragon 28 on April 21, 2025, to strengthen its presence in the foot and ankle surgical market.
• Launched a new manufacturing optimization initiative in 2026 to improve production efficiency and lower costs.
• Invested $101.2 million in technology ownership rights during the six-month period ended June 30, 2026.
• Authorized a $1.5 billion share repurchase program in Feb. 2026 to return capital to its shareholders.

Reaching Patients Worldwide

The company maintains a broad global presence with significant operations across the Americas, Europe, and Asia Pacific. It focuses on integrating digital tools like the ROSA robotic-assisted platform to help surgeons perform elective procedures with greater precision.

Financial Performance in Review

• Net sales were $4.3 billion in the six-month period ended June 30, 2026, up 7.0% year over year.
• Net earnings reached $436.5 million in the six-month period ended June 30, 2026, up from $334.9 million in the prior year period.
• Cash flow from operating activities was $807.2 million in the six-month period ended June 30, 2026.
• Market capitalization was $16.5 billion in Q2 2026, down 8.3% year over year.
• The company reported a price-to-earnings ratio of 20.9 in Q2 2026, compared to 29.6 in Q2 2025.

Evolution of Medical Care

Zimmer Biomet has transitioned from a traditional hardware manufacturer into a specialized medical technology provider. Its focus on robotics and data-driven surgical solutions helps it adapt to modern healthcare needs and maintain its position in the orthopedic market.